RSL3 Drives Ferroptosis Through GPX4 Inactivation and ROS Production in Colorectal Cancer

• Published in: Frontiers in pharmacology 2018-11, Vol.9, p.1371-1371
• Main Authors: Sui, Xinbing, Zhang, Ruonan, Liu, Shuiping, Duan, Ting, Zhai, Lijuan, Zhang, Mingming, Han, Xuemeng, Xiang, Yu, Huang, Xingxing, Lin, Haoming, Xie, Tian
• Format: Article
• Language: English
• Subjects: colorectal cancer; ferroptosis; glutathione peroxidase 4; Pharmacology; reactive oxygen species; RSL3
• ISSN: 1663-9812; 1663-9812
• DOI: 10.3389/fphar.2018.01371

Ferroptosis is an iron-dependent, oxidative cell death, and is characterized by iron-dependent accumulation of reactive oxygen species (ROS) within the cell. It has been implicated in various human diseases, including cancer. Recently, ferroptosis, as a non-apoptotic form of cell death, is emerging in specific cancer types; however, its relevance in colorectal cancer (CRC) is unexplored and remains unclear. Here, we showed that ferroptosis inducer RSL3 initiated cell death and ROS accumulation in HCT116, LoVo, and HT29 CRC cells over a 24 h time course. Furthermore, we found that ROS levels and transferrin expression were elevated in CRC cells treated with RSL3 accompanied by a decrease in the expression of glutathione peroxidase 4 (GPX4), indicating an iron-dependent cell death, ferroptosis. Overexpression GPX4 resulted in decreased cell death after RSL3 treatment. Therefore, RSL3 was able to induce ferroptosis on three different CRC cell lines in a dose- and time-dependent manner, which was due to increased ROS and an increase in the cellular labile iron pool. Moreover, this effect was able to be reversed by overexpression of GPX4. Taken together, our results suggest that the induction of ferroptosis contributed to RSL3-induced cell death in CRC cells and ferroptosis may be a pervasive and dynamic form of cell death for cancer treatment.